Favorable outcome of extended treatment with adding pegylated Interferonα-2a to entecavir for HBeAg-positive chronic hepatitis B: a case report.

Ying Zhang, Xuefeng Li, Jiao Xu, Yong Zhang

Abstract readCase Reports

In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ying ZhangSixth Department of Liver Diseases, Dalian Sixth People Hospital Dalian 116031, Liaoning Province, China.

Xuefeng LiDepartment of Infectious Diseases, The Second Hospital of Dalian Medical University Dalian 116027, China.

Jiao XuSixth Department of Liver Diseases, Dalian Sixth People Hospital Dalian 116031, Liaoning Province, China.

Yong ZhangSixth Department of Liver Diseases, Dalian Sixth People Hospital Dalian 116031, Liaoning Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) surface antigen (HBsAg) to anti-HBsAg (anti-HBs) seroconversion is the best and final objective of all available chronic hepatitis B (CHB) therapies. Unfortunately, this goal is not commonly obtained with current therapeutic approaches. Here, we reported a case that a Chinese CHB patient successfully achieved HBsAg seroconversion under extended individualized therapeutic schedule. At 48 weeks after entecavir (ETV) monotherapy, pegylated interferon alpha-2a (PEG-IFN-α-2a) was added, and the titers of HBsAg decreased and HBsAg loss was achieved. After 96 weeks of combination therapy, PEG-IFN-α-2a was stopped and ETV monotherapy was continued for additional 24 weeks. HBsAg seroconversion was sustained, 48 weeks after the end of all treatment.

Indexed as

Chronic hepatitis BentecavirPEG-IFN-α-2asequential combination

Identifiers

PMID26770617

PMCPMC4694517

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.